The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer

Muslim L. Alabdullah(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Paul M. Moseley(Nottingham University Hospitals NHS Trust), Stephen Chan(Heidelberg University), Dena A. J. Ahmad(University of Nottingham)

Journal of Obstetrics and Gynaecology

February 4, 2019

10.1080/01443615.2018.1534091

Cited by 16

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

|Journal of Clinical Oncology|1999|639

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374